Integra LifeSciences

IARTPhase 3

Founded 1989integralife.com

Integra LifeSciences is a publicly traded global leader in medical technologies, with a core mission of restoring lives through impactful innovation in neurosurgery and tissue reconstruction. The company has built a highly differentiated portfolio through strategic acquisitions, including Codman® Neurosurgery and Acclarent, establishing itself as the global leader in neurosurgical products. Under the leadership of President & CEO Mojdeh Poul, Integra is focused on strengthening its quality systems, advancing its innovation pipeline, and executing a transformation to drive long-term growth and value.

Market Cap

$1.1B

Founded

1989

IART · Stock Price

USD 14.20+2.22 (+18.53%)

Historical price data

AI Company Overview

Technology Platform

Core expertise in collagen-based regenerative matrices for tissue repair and advanced surgical systems, including ultrasonic aspiration for precise tissue removal. The platform supports dermal, dural, nerve, and soft tissue reconstruction.

Pipeline Snapshot

11 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
INTEGRA™ Flowable Matrix (Collagen)	Diabetes	Approved
DSC127 + placebo vehicle gel	Diabetic Foot Ulcers	Phase 3
0.03% DSC127 topical gel	Diabetic Foot Ulcer	Phase 3
BioDFence G3	Prostate Cancer	Phase 3
DSC127 + placebo vehicle gel + Standard of Care gel, Aquasite	Diabetic Foot Ulcers	Phase 3

Funding History

Total raised: $42M

IPO$42MUndisclosedNov 16, 1995

Opportunities

Growth opportunities include expanding indications for flagship systems like CUSA® into adjacent surgical fields (e.g., cardiac), leveraging the 2024 Acclarent acquisition to grow in the ENT market, and driving adoption of its regenerative technologies across its core surgical and wound care franchises.

Operational improvements in supply chain and quality are expected to unlock underlying demand.

Risk Factors

Key risks include ongoing challenges with regulatory compliance and quality system remediation, execution risks associated with its operational transformation plan, integration of acquisitions, and exposure to pricing pressure and procedure volume fluctuations in its core hospital-based markets.

Competitive Landscape

Integra competes with large, diversified medtech companies like Medtronic and Stryker in neurosurgery, and with specialized players like Organogenesis and Smith & Nephew in wound care. Its differentiation lies in its deep specialization, a portfolio of clinically-proven, gold-standard products, and the ability to provide integrated solutions across a surgical procedure.

Publications

Patents

Pipeline